About Recordati SpA 
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates 
Company Details
Via M. Civitali, 1 , MILANO None : 20148
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Alfredo Altavilla
Non-Executive Chairman of the Board
Dr. Andrea Recordati
Chief Executive Officer, Executive Director
Guido Guidi
Vice Chairman of the Board
Adv. Michaela Castelli
Lead Independent Non-Executive Director
Francesco Balestrieri
Director
Piergiorgio Peluso
Independent Director
Ms. Silvia Elisabetta Candini
Non-Executive Independent Director
Revenue and Profits:
Net Sales:
644 Million
(Quarterly Results - Jun 2025)
Net Profit:
91 Million
Pharmaceuticals & Biotechnology
EUR 9,883 Million ()
25.00
NA
22.92%
0.86
22.64%
5.13






